{"entity":{"id":"nct01305655","kind":"trial","name":"Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL","aka":[],"tldr":"A phase 3 trial of Glucarpidase in Acute lymphoblastic leukaemia, run by Nordic Society for Pediatric Hematology and Oncology, completed.","summary":"Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL is a phase 3 interventional study registered as NCT01305655 by Nordic Society for Pediatric Hematology and Oncology, with 47 participants recorded, started 2008-07 and reaching its primary completion in 2014-12. Interventions recorded: Glucarpidase. Conditions recorded: Acute Lymphoblastic Leukemia (ALL).\n\nLinked to the drug Glucarpidase because the registry names it among its interventions and Acute lymphoblastic leukaemia among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01305655","url":"https://clinicaltrials.gov/study/NCT01305655"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":["glucarpidase"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01305655","phase":"3","setting":"Glucarpidase (CPG2) Effect on Severe Delayed Methotrexate-clearance in Children Treated With High-dose Methotrexate in Acute Lymphoblastic Leukemia (ALL)","sponsor":"Nordic Society for Pediatric Hematology and Oncology","enrolled":47,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01305655/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"drug":[{"id":"glucarpidase","kind":"drug","name":"Glucarpidase","route":"/drugs/glucarpidase/"}]}}